Literature DB >> 10835519

Increased midkine expression in hepatocellular carcinoma.

M Kato1, T Shinozawa, S Kato, A Awaya, T Terada.   

Abstract

CONTEXT: Midkine (MK) is a novel heparin-binding growth factor whose gene was identified in embryonal carcinoma cells in early stages of retinoic acid-induced differentiation.
OBJECTIVE: To examine the overexpression of MK in hepatocellular carcinoma (HCC).
METHODS: Seventy-seven primary HCC specimens from patients aged 17 to 72 years (63 men and 14 women) were examined. Histologically, 16 cases of HCC were classified as the well-differentiated type, 50 cases as the moderately differentiated type, and 11 cases as the poorly differentiated type. Immunohistochemical analysis was performed using a rat immunoglobulin G2a monoclonal antibody against the carboxyl terminal region of human MK. In situ hybridization was also performed on 20 HCC samples.
RESULTS: We successfully applied this monoclonal antibody against MK to analyze archival paraffin sections. The cancer tissues showed a positive reaction to this antibody, in which there was an intense reaction in their cytoplasm. Approximately one third of the individuals with HCC (26/77) had tumor cells that expressed MK, and these were classified into the following types: moderately differentiated (20/50), well differentiated (3/16), and poorly differentiated (3/11). The in situ hybridization analysis revealed that the signals of MK transcripts were found in the cytoplasm of the cancer cells; the distribution and localization of the MK transcripts' signals determined by in situ hybridization analysis were similar to those obtained by immunohistochemical analysis.
CONCLUSIONS: Hepatocellular carcinoma expressed increased MK at the messenger RNA and protein level.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10835519     DOI: 10.5858/2000-124-0848-IMEIHC

Source DB:  PubMed          Journal:  Arch Pathol Lab Med        ISSN: 0003-9985            Impact factor:   5.534


  18 in total

1.  The clinical and prognostic significance of midkine in breast cancer patients.

Authors:  Fuguang Li; Peijun Tian; Jun Zhang; Changyuan Kou
Journal:  Tumour Biol       Date:  2015-07-10

2.  Silencing of high-mobility group box 2 (HMGB2) modulates cisplatin and 5-fluorouracil sensitivity in head and neck squamous cell carcinoma.

Authors:  Nazia Syed; Sandip Chavan; Nandini A Sahasrabuddhe; Santosh Renuse; Gajanan Sathe; Vishalakshi Nanjappa; Aneesha Radhakrishnan; Remya Raja; Sneha M Pinto; Anand Srinivasan; T S Keshava Prasad; Kotteazeth Srikumar; Harsha Gowda; Vani Santosh; David Sidransky; Joseph A Califano; Akhilesh Pandey; Aditi Chatterjee
Journal:  Proteomics       Date:  2015-01       Impact factor: 3.984

3.  Expression of midkine and its clinical significance in esophageal squamous cell carcinoma.

Authors:  Ying-Jia Ren; Qing-Yun Zhang
Journal:  World J Gastroenterol       Date:  2006-04-07       Impact factor: 5.742

4.  Complete regression of human malignant mesothelioma xenografts following local injection of midkine promoter-driven oncolytic adenovirus.

Authors:  Shuji Kubo; Yoshiko Kawasaki; Norie Yamaoka; Masatoshi Tagawa; Noriyuki Kasahara; Nobuyuki Terada; Haruki Okamura
Journal:  J Gene Med       Date:  2010-08       Impact factor: 4.565

5.  S-adenosylmethionine in the chemoprevention and treatment of hepatocellular carcinoma in a rat model.

Authors:  Shelly C Lu; Komal Ramani; Xiaopeng Ou; Mark Lin; Victor Yu; Kwangsuk Ko; Ryan Park; Teodoro Bottiglieri; Hidekazu Tsukamoto; Gary Kanel; Samuel W French; José M Mato; Rex Moats; Edward Grant
Journal:  Hepatology       Date:  2009-08       Impact factor: 17.425

6.  Evaluation of midkine as a diagnostic serum biomarker in hepatocellular carcinoma.

Authors:  Wen-Wei Zhu; Jia-Jian Guo; Lei Guo; Hu-Liang Jia; Ming Zhu; Ju-Bo Zhang; Christopher A Loffredo; Marshonna Forgues; Hua Huang; Xu-Jian Xing; Ning Ren; Qiong-Zhu Dong; Hai-Jun Zhou; Zheng-Gang Ren; Nai-Qing Zhao; Xin Wei Wang; Zhao-You Tang; Lun-Xiu Qin; Qing-Hai Ye
Journal:  Clin Cancer Res       Date:  2013-05-29       Impact factor: 12.531

7.  Oncolytic virotherapy for osteosarcoma using midkine promoter-regulated adenoviruses.

Authors:  M Takagi-Kimura; T Yamano; M Tagawa; S Kubo
Journal:  Cancer Gene Ther       Date:  2014-02-28       Impact factor: 5.987

8.  Enhanced antitumor efficacy of fiber-modified, midkine promoter-regulated oncolytic adenovirus in human malignant mesothelioma.

Authors:  Misato Takagi-Kimura; Tomoki Yamano; Atsuko Tamamoto; Nobutaka Okamura; Haruki Okamura; Tomoko Hashimoto-Tamaoki; Masatoshi Tagawa; Noriyuki Kasahara; Shuji Kubo
Journal:  Cancer Sci       Date:  2013-09-23       Impact factor: 6.716

9.  Enhanced therapeutic effects of combined chemotherapeutic drugs and midkine antisense oligonucleotides for hepatocellular carcinoma.

Authors:  Li-Cheng Dai; Xiang Wang; Xing Yao; Yong-Liang Lu; Jin-Liang Ping; Jian-Fang He
Journal:  World J Gastroenterol       Date:  2007-04-07       Impact factor: 5.742

Review 10.  Midkine (MDK) growth factor: a key player in cancer progression and a promising therapeutic target.

Authors:  Panagiota S Filippou; George S Karagiannis; Anastasia Constantinidou
Journal:  Oncogene       Date:  2019-12-04       Impact factor: 9.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.